---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-042859"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:37:22.794922+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharmaceuticals receives Nasdaq bid price deficiency notice; 180 days to regain compliance

## Summary
- Nasdaq letter dated April 5, 2023: ADS bid price below $1.00 for 30 consecutive business days.
- Company has until October 2, 2023 to regain compliance via closing bid >= $1.00 for 10 consecutive days.
- If not compliant by Oct 2, company may request additional 180-day grace period if meeting other listing standards.
- No immediate effect on Nasdaq listing; company is working on cure but cannot assure compliance.

## SEC filing metadata
- accession: 0001104659-23-042859
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923042859/0001104659-23-042859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923042859/tm2312054d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-042859
- JSON: https://secwatch.observer/filing/0001104659-23-042859.json
- Plain text: https://secwatch.observer/filing/0001104659-23-042859.txt

## Key facts
- Listing & Compliance Notices
  Quoin Pharmaceuticals, Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: April 5, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per American Depositary Share (“ADS”) representing 5,000 ordinary shares of the Company was below the required minimum of $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company has a period of one hundred eighty (180) calendar days, or until
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923042859/0001104659-23-042859-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.